Reuters logo
BRIEF-Merrimack Pharma estimates will incur charges for one-time termination benefits in connection with corporate restructuring of about $4.5-$5.5 mln
October 3, 2016 / 11:57 AM / a year ago

BRIEF-Merrimack Pharma estimates will incur charges for one-time termination benefits in connection with corporate restructuring of about $4.5-$5.5 mln

Oct 3 (Reuters) - Merrimack Pharmaceuticals Inc

* Reduction in headcount will not impact company’s commercial team or execution of ONIVYDE‘S commercial launch and label expansion

* Estimates will incur charges for one-time termination benefits in connection with corporate restructuring of about $4.5-$5.5 million Source text: [bit.ly/2dDBdCm] Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below